%D8%A5%D9%8A%D9%86%D9%88%D9%83%D8%B3%D8%A7%D8%A8%D8%A7%D8%B1%D9%8A%D9%86Enoxaparin-NatriumEnoxaparin_sodiumEnoxaparina_s%C3%B3dicaEnoxaparineEnoxaparina%E3%82%A8%E3%83%8E%E3%82%AD%E3%82%B5%E3%83%91%E3%83%AA%E3%83%B3%E3%83%8A%E3%83%88%E3%83%AA%E3%82%A6%E3%83%A0%E0%AC%8F%E0%AC%A8%E0%AD%8B%E0%AC%95%E0%AD%8D%E0%AC%B8%E0%AC%BE%E0%AC%AA%E0%AC%BE%E0%AC%B0%E0%AC%BF%E0%AC%A8_%E0%AC%B8%E0%AD%8B%E0%AC%A1%E0%AC%BC%E0%AC%BF%E0%AC%85%E0%AC%AEEnoksaparynaEnoxaparina_s%C3%B3dica%D0%AD%D0%BD%D0%BE%D0%BA%D1%81%D0%B0%D0%BF%D0%B0%D1%80%D0%B8%D0%BD_%D0%BD%D0%B0%D1%82%D1%80%D0%B8%D1%8FEnoksaparin_natrijumEnoksaparin_natrijum%D0%95%D0%BD%D0%BE%D0%BA%D1%81%D0%B0%D0%BF%D0%B0%D1%80%D0%B8%D0%BDEnoxaparinQ416516%E4%BE%9D%E8%AF%BA%E8%82%9D%E7%B4%A0%E9%92%A0
about
sameAs
Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU PatientsAnti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid ObesityLenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeBelow Knee DVT StudyEffect of LMWH on Pregnancy Outcome in Women With Multiple Failures of IVF-ETProphylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal SurgeryA Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip ArthroplastyStudy of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture SurgeryA Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee ArthroplastyLow Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid AntibodiesEvaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement SurgeryEvaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal SurgeryThrombelastography Based Dosing of EnoxaparinA Single-Dose Study to Examine the Within Subject Variability of Clexane® in Healthy Adult Subjects Under Fasting ConditionsComparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin ThromboprophylaxisComparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult SubjectsAnticoagulation Regimens in Pregnant Patients With Prosthetic Heart ValvesBioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.Anticoagulation Length in Cancer Associated ThrombosisPharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous AdministrationPharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single DoseComparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary SyndromePatients With High-risk Acute Coronary Syndrome Without ST-segment ElevationLow Molecular Weight Heparin for Hemodialysis AnticoagulationA Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip ArthroplastyLow-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid SyndromeEnoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)Anticoagulation Post Laparoscopic SplenectomyEvaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture SurgerySTEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted MobilityIdentification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With CancerResidual Anti-Xa Activity After Last Treatment Dose of EnoxaparinStudy of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy VolunteersA Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic SurgeriesOral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic MalignancyLovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI)Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers
P4844
Drosophila as a tool for the rapid assessment of chemicals for teratogenicity.Investigation of Drosophila for Teratogenic ScreeningEnoxaparin in the treatment of severe traumatic brain injury: A randomized clinical trialA Reflection on the Use of Enoxaparin Based on Three Case ReportsEnoxaparin (or plus aspirin) for the prevention of recurrent miscarriage: A meta-analysis of randomized controlled studiesProphylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literatureEvaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairmentA Critical Evaluation of Enoxaparin Dose Adjustment Guidelines in ChildrenPharmaceutical "New Prior Knowledge": Twenty-First Century Assurance of Therapeutic EquivalenceEfficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II StudyEvaluation of Venous Thromboembolic Event Prophylaxis in Hospitalized Cancer Patients: A Single-Centered Retrospective Study
P921
Q61917756-67C8FCC8-514B-42B0-AC2B-563A2D09C22CQ61975376-EB724B58-3BE6-4B72-A683-3E9AC1A74AB8Q63571282-6247C5B3-A56B-4EE4-AD73-14596AACEF85Q63584710-2B1FECB4-3364-424D-9FCC-A9265BCDE708Q63596834-04A7AFFA-DE59-4F81-A315-F1C581C08CCEQ63813675-64B40E7C-3831-4CE2-A2A2-A5D3793B10ECQ63828956-99B3164E-6162-4AA7-A05B-10C9A2437486Q63828960-FECA4A52-9506-4DEF-A1C1-70470E4E05D6Q63828964-764F5DB1-3E77-4CBD-AF0B-B3C7C9A0B19FQ63842291-0E3B622D-827A-47CA-8FE3-EFC1D6F44D43Q64043570-61A5C1DB-28BD-42F8-9F81-F75FED8D31ADQ64046113-423B6DCD-203A-4BEE-81D1-1312EA7764E2Q64171443-DE6F7D46-982E-462C-A8F1-BCADCE9EB0E2Q64221738-94AEFF29-539A-4033-96D7-34DCD8EED826Q64222734-513B162E-7BFA-4ECD-A099-205DBF6A8FC6Q64396233-4D566DD3-E7E7-46E2-B165-53B2F5481A6FQ64601404-A15D25A3-6170-4027-86FF-AB13F624F358Q64602317-407532F8-9F11-47C7-AC7A-09B3F38D2617Q64607182-5B9A35B8-3859-4EBD-AEF9-E6EB0DB0A3D3Q64631249-F21D79B1-5C20-449A-A5E7-CFDBB9AD9259Q64640848-392AB002-3B2E-4BFA-819B-9669A3481AD3Q64640849-3C713E31-104E-4863-A3F6-F1C8A219FBC8Q64641300-1D866026-9BEB-4387-95FA-F03690A1936FQ64650403-74E124CA-D3A6-4870-8E83-1CA4C370F3D7Q64650427-E39BFC66-7A8C-45FF-8F5F-D50326F1B95BQ64652939-29318746-B937-457E-BA6F-22AA9D1C3D6CQ64657291-7A89DFEE-83EC-43D1-BDF2-55CBDB0471AEQ64715697-FD42000B-FCB6-48E1-8F12-C2536E397A61Q64715967-6DB59289-BD2D-4F05-B90F-8136B41DDC2BQ64717415-6E73A5BE-A1D0-413D-8646-882142BB4758Q64718103-E8F0BCEB-28FE-4DD1-9385-792B01A9D17FQ64718903-5ED92C9E-1FE1-4C4C-B6E3-4C7C46D27300Q64721354-8535D5AD-1870-4C8E-AAD8-6AB4CDAD476BQ64790894-D78C7610-273D-49F9-87F1-F51FEBB6F213Q64807291-A258667F-93FD-476B-B80F-ABD83B999718Q65348298-EAC5ADAF-DC46-41A9-914B-251B1C81E293Q65348552-21BAC7F1-BC2E-451D-827D-0A43718B7B47Q65349152-D926F3D9-BF47-4A5D-B2FF-578F179D5A4CQ65352867-6E6D60B1-427F-47B8-BC7A-59BB84CF9771Q65354250-D4658BFF-9A42-49E0-8335-DD1960A8B462
P4844
Q24169604-929C3560-F7BF-4EF9-A6C8-6DED8B45E3CAQ26330676-BCD1CB27-A156-440A-8745-E2027770F7BAQ61809955-85C25EBB-EEB6-476C-BE16-E081369CE3EAQ61812500-99360044-23AF-4891-A2A6-1618C2D95AB2Q61836682-DDFD70BC-D393-4379-81DB-F745F26FF9F2Q64039523-47DB04DF-DFBF-4F91-9F0C-3CA19275584DQ64063315-DCB985FC-1954-474B-B0B1-35F536F657EBQ64080547-AA396453-C642-4004-9610-A5B35A07D397Q64100682-320C95E8-C0D6-42EC-90CF-D5EB637058BFQ64108986-5E6F7BCB-F377-4F5A-A92A-18C482886356Q64237505-CDEA54DA-0EBA-4C80-BD97-38F9D68F9329
P921
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemical compound: low molecular weight heparins
@en
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische stof
@nl
component quimic
@oc
name
Enoksaparin natrijum
@sh
Enoksaparin natrijum
@sr
Enoksaparyna
@pl
Enoxaparin
@de
Enoxaparin
@nl
Enoxaparin
@vi
Enoxaparina
@es
enoxaparin
@en
enoxaparina
@it
enoxaparina
@pt
type
label
Enoksaparin natrijum
@sh
Enoksaparin natrijum
@sr
Enoksaparyna
@pl
Enoxaparin
@de
Enoxaparin
@nl
Enoxaparin
@vi
Enoxaparina
@es
enoxaparin
@en
enoxaparina
@it
enoxaparina
@pt
altLabel
Clexane
@de
Clexane
@it
Clexane
@pl
Clexane®
@en
Enoxaparin
@pl
Enoxaparine
@fr
Lovenox®
@en
PK-10169
@en
RP-54563
@en
enoxaparin sodium
@en
prefLabel
Enoksaparin natrijum
@sh
Enoksaparin natrijum
@sr
Enoksaparyna
@pl
Enoxaparin
@de
Enoxaparin
@nl
Enoxaparin
@vi
Enoxaparina
@es
enoxaparin
@en
enoxaparina
@it
enoxaparina
@pt
P31
P486
P6366
P646
P662
P665
P1748
P2067
1,134.006995
P231
679809-58-6
P232
P233
CC(=O)NC1C(C(C(OC1O)COS(=O)(=O ...... )O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
P234
1S/C26H42N2O37S5/c1-4(30)27-7- ...... 47,48)(H,49,50,51)(H,52,53,54)
P235
HTTJABKRGRZYRN-UHFFFAOYSA-N
P2566
100.029.698
P267
P274
C₂₆H₄₂N₂O₃₇S₅